

Bogotá Declaration

Intention to cooperate for the Safe Use of medication and Pharmacovigilance Development in Latin America

The safe use of medication is a key strategy in patient safety and is a duty of each party involved with their proper use, ensuring every effort is made to promote maximum effectiveness and accurate safety.

In this regard, the representatives of the countries, organizations and associations in the Third Symposium of the Latin American Chapter of ISoP who met in Bogota on 25 and 26 August 2016, declare their intention to cooperate in order to promote the safe use of medicines and the development of Pharmacovigilance in Latin America, on behalf of Public Health and Patient Safety.

Therefore, we consider focusing efforts in order to promote the safe use of medicines and the development of Pharmacovigilance in Latin America through the following objectives and strategies:

- To generate proposals for the harmonization of Pharmacovigilance in Latin America.
- To study the impact of pharmacovigilance on public health and the management and sustainability of health systems.
- To make all different parties more aware about the impact of Pharmacovigilance.
- Promote active participation in national and international arenas where this subject is raised.
- To promote the culture of safe use of medications.
- To facilitate the establishment of the guiding principles regarding Pharmacovigilance for the region.

Strategic axes:

- Creation of proposals about pharmaceutical legislation focused on the safe use of medication.
- Assessing the impact of pharmacovigilance on health costs.
- Promotion of culture of safe use, risk communication and training in Pharmacovigilance.
- Creation of strategies for implementing Pharmacovigilance models.
- Creation of opportunities for the participation of the patient and the community in general in programs of Pharmacovigilance and safe use of medicines.

Key Parties

- Regulatory affairs and Healthcare authorities.
- Healthcare professionals.
- Health Service Providers.
- Pharmaceutical industry.



- Patients and the community in general.
- Academy.
- Healthcare organizations.

As part of the strategic approach and to achieve these objectives, it is proposed that all parties take integrated action looking for a broad approach towards risk management:

- a. Promotion of the development of surveillance systems for adverse events, adverse drug reactions and drug-related problems.
- b. Strategies for safe use in hospitals, ambulatory settings and transitional settings.
- c. Strategies for safe use of high-risk medications
- d. Optimizing the use of antimicrobials and support for the control of bacterial resistance
- e. Developing skills for the execution of research in pharmacovigilance and other issues regarding pharmacoepidemiology.
- f. Formation of working groups for generating proposals.
- g. Generation of proposals in order to consolidate best practices built by different groups which are applicable to Latin American countries.
- h. To formalize a network of contacts that allows a wide dissemination and the exchange of information and experiences.

Development of these strategies, work plans, timelines and indicators (structure, process, outcome and impact) will be established for each working group and the impact of the results of these activities will be obtained by these groups. The Colombian Association of Pharmacovigilance will drive the impetus and implementation of the commitments in this statement.

As agreed by all parties, this current document is signed on 26 August 2016 in Bogotá by attendees.